Latest Development Pipeline News

Great Divide Mining Ltd (ASX: GDM) has received its first cash payment of USD 78,480.35 from gold concentrate sales at its Challenger Gold Mine, marking a key milestone in its transition from explorer to producer within three years of listing.

HomeCo Daily Needs REIT has recorded a $92 million gross valuation increase driven by net operating income growth, maintaining strong operational metrics and reaffirming its FY26 distribution and FFO guidance.

Finbar Group has wrapped up its $114 million Bel-Air Apartments development in Belmont with titles issued and settlements set to begin late June. The company maintains its FY26 net profit guidance between $18 million and $22 million despite some settlement timing uncertainty.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Cedar Woods Properties has secured over 740 new townhouse and apartment lots across Victoria and Queensland, boosting its medium-term development pipeline while maintaining a strong sales and earnings outlook.

Evion Group’s Panthera Graphite Technologies joint venture posted a US$530,000 EBITDA in its first full year of commercial production, operating at just 20-25% capacity and setting the stage for substantial earnings growth.

Ingenia Communities Group (ASX: INA) confirms it is on track to hit the top of its FY26 guidance, underpinned by a strong development pipeline exceeding 8,000 potential land lease lots and resilient holiday operations.

Godolphin Resources has agreed to sell its 49% interest in the Calarie Project to Adavale Resources in a deal structured around shares and long-dated options, aligning with a strategic shift towards its core assets.

Stride Property Group posted a 44% jump in FY26 profit after tax to $31.3 million, driven by strategic portfolio moves, management fee growth, and sustainability progress. The group maintained an 8.0cps dividend amid a $1.4 billion diversified property portfolio and a strong balance sheet.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Beetaloo Energy has wrapped up its $5 million Share Purchase Plan with strong shareholder uptake, pending final approval at the upcoming AGM for new share issuance.

BWP Group has successfully closed its $228 million fully underwritten entitlement offer, with retail investors contributing $19 million and institutional investors covering the balance.